Project Zero Delay accelerates drug's path to clinical trial

A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Centre and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical Oncology published online on 3 August...

Read the whole article on

More from